interleukin-33 (IL-33) inhibitor
Sep 25, 2018
Notizia
The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
